What the company actually pays, and whether its own cash supports it.
Dividends view
Yield
0.42%
Annual Rate
CNY 0.04Paid semi-annual
Payout Ratio
66.7%Moderate
Payback Period
98.0 yr
Last Ex-Dividend
Dec 15, 2025
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
2.03BCNY
301.10M · vs all stocks (USD)
Updated Aug 20, 2026
Revenue (TTM)
5.23BCNY
776.55M · vs all stocks (USD)
Updated Aug 20, 2026
Profit Margin
-4.58%
vs Pharmaceutical Retailers peers
Updated Aug 20, 2026
Beta
0.6050x
vs all stocks
Updated Aug 20, 2026
52-Week Change
-18.95%
vs all stocks
Updated Aug 20, 2026
Forward Annual Dividend Yield
0.42%
vs all stocks
Updated Aug 20, 2026
Market Capitalization
2.03BCNY
301.10M · vs all stocks (USD)
Updated Aug 20, 2026
Enterprise Value
5.33BCNY
790.91M · vs all stocks (USD)
Updated Aug 20, 2026
Price to Sales (TTM)
0.3889x
vs Pharmaceutical Retailers peers
Updated Aug 20, 2026
Price to Book (MRQ)
1.36x
vs Pharmaceutical Retailers peers
Updated Aug 20, 2026
Enterprise to Revenue
1.02x
vs Pharmaceutical Retailers peers
Updated Aug 20, 2026
Enterprise to EBITDA
35.44x
vs Pharmaceutical Retailers peers
Provider-reported. Enterprise Value ÷ EBITDA (TTM) on this page gives 21.21×.Updated Aug 20, 2026
Gross Margin
17.23%
vs Pharmaceutical Retailers peers
Updated Aug 20, 2026
Profit Margin
-4.58%
vs Pharmaceutical Retailers peers
Updated Aug 20, 2026
Operating Margin
2.45%
vs Pharmaceutical Retailers peers
Updated Aug 20, 2026
Return on Assets (TTM)
0.79%
vs Pharmaceutical Retailers peers
Updated Aug 20, 2026
Return on Equity (TTM)
-13.24%
vs Pharmaceutical Retailers peers
Updated Aug 20, 2026
Revenue (TTM)
5.23BCNY
776.55M · vs all stocks (USD)
Updated Aug 20, 2026
Revenue per Share (TTM)
24.22CNYUpdated Aug 20, 2026
Quarterly Revenue Growth
6.50%
vs Pharmaceutical Retailers peers
Updated Aug 20, 2026
Gross Profit (TTM)
945.83MCNY
140.48M · vs all stocks (USD)
Updated Aug 20, 2026
EBITDA (TTM)
251.11MCNY
37.29M · vs all stocks (USD)
Updated Aug 20, 2026
Net Income (TTM)
-239.64MCNY
-35.59M · vs all stocks (USD)
Updated Aug 20, 2026
Quarterly Earnings Growth (YoY)
89.70%
vs Pharmaceutical Retailers peers
Updated Aug 20, 2026
Operating Cash Flow (TTM)
-15.71MCNY
-2.33M · vs all stocks (USD)
Updated Aug 20, 2026
Levered Free Cash Flow (TTM)
-127.73MCNY
-18.97M · vs all stocks (USD)
Updated Aug 20, 2026
Forward Annual Dividend Rate
0.0440CNYUpdated Aug 20, 2026
Forward Annual Dividend Yield
0.42%
vs all stocks
Updated Aug 20, 2026
Trailing Annual Dividend Rate
0.1038CNYUpdated Aug 20, 2026
Trailing Annual Dividend Yield
1.00%
vs all stocks
Updated Aug 20, 2026
Payout Ratio
66.67%
vs Pharmaceutical Retailers peers
Provider-reported. Trailing Annual Dividend Rate ÷ Diluted EPS (TTM) on this page gives -8.87%.Updated Aug 20, 2026
Minority Interest (Equity)
105.08MCNYFY2025 · Dec 31, 2025
Revenue
5.14BCNYFY2025 · Dec 31, 2025
Cost of Goods Sold
4.21BCNYFY2025 · Dec 31, 2025
Gross Profit
936.34MCNYFY2025 · Dec 31, 2025
Operating Income
109.52MCNY
16.27M · vs all stocks (USD)
FY2025 · Dec 31, 2025
Pre-tax Income
-220.43MCNYFY2025 · Dec 31, 2025
Income Tax Expense
8.32MCNYFY2025 · Dec 31, 2025
Net Income
-228.75MCNYFY2025 · Dec 31, 2025
EBIT
-113.67MCNYFY2025 · Dec 31, 2025
EBITDA (Income Statement)
251.11MCNYFY2025 · Dec 31, 2025
Research & Development
11.85MCNYFY2025 · Dec 31, 2025
Selling, General & Administrative
239.11MCNYFY2025 · Dec 31, 2025
Other Operating Expenses
26.35MCNYFY2025 · Dec 31, 2025
Non-operating Interest Income
3.31MCNYFY2025 · Dec 31, 2025
Non-operating Interest Expense
106.76MCNYFY2025 · Dec 31, 2025
EPS (Basic)
-1.18CNYFY2025 · Dec 31, 2025
EPS (Diluted)
-1.18CNYFY2025 · Dec 31, 2025
Basic Shares Outstanding
205.47MSharesFY2025 · Dec 31, 2025
Diluted Shares Outstanding
205.47MSharesFY2025 · Dec 31, 2025
Net Income from Continuing Operations
-228.75MCNYFY2025 · Dec 31, 2025
Minority Interests (P&L)
-13.71MCNYFY2025 · Dec 31, 2025
Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025
Operating Cash Flow
-544.33MCNYFY2025 · Dec 31, 2025
Free Cash Flow
-648.79MCNYFY2025 · Dec 31, 2025
Cash & Cash Equivalents (End of Period)
254.59MCNYFY2025 · Dec 31, 2025
Starting Profit (CF Statement)
-228.75MCNYFY2025 · Dec 31, 2025
Other Non-cash Items
136.30MCNYFY2025 · Dec 31, 2025
Change in Accounts Receivable (CF)
-388.47MCNYFY2025 · Dec 31, 2025
Change in Other Assets/Liabilities
-63.41MCNYFY2025 · Dec 31, 2025
Capital Expenditures
-104.46MCNYFY2025 · Dec 31, 2025
Net Acquisitions
-109.53MCNYFY2025 · Dec 31, 2025
Sale of Investments
688.55KCNYFY2025 · Dec 31, 2025
Other Investing Activity
-7.52MCNYFY2025 · Dec 31, 2025
Net Investing Cash Flow
-220.81MCNYFY2025 · Dec 31, 2025
Long-term Debt Issuance
2.66BCNYFY2025 · Dec 31, 2025
Long-term Debt Payments
-2.49BCNYFY2025 · Dec 31, 2025
Common Dividends Paid
-111.99MCNYFY2025 · Dec 31, 2025
Other Financing Charges
79.68MCNYFY2025 · Dec 31, 2025
Net Financing Cash Flow
143.94MCNYFY2025 · Dec 31, 2025
Shares Outstanding
205.40MSharesUpdated Aug 20, 2026
Float Shares
107.76MSharesUpdated Aug 20, 2026
% Held by Insiders
49.57%
vs all stocks
Updated Aug 20, 2026
% Held by Institutions
5.92%
vs all stocks
Updated Aug 20, 2026
Total Cash (MRQ)
529.87MCNY
78.70M · vs all stocks (USD)
Updated Aug 20, 2026
Total Cash per Share (MRQ)
2.58CNYUpdated Aug 20, 2026
Total Debt (MRQ)
3.67BCNY
544.33M · vs all stocks (USD)
Updated Aug 20, 2026
Total Debt to Equity (MRQ)
2.29x
vs Pharmaceutical Retailers peers
Updated Aug 20, 2026
Current Ratio (MRQ)
1.01x
vs Pharmaceutical Retailers peers
Updated Aug 20, 2026
Book Value per Share (MRQ)
7.27CNYUpdated Aug 20, 2026
Total Assets
6.34BCNY
941.16M · vs all stocks (USD)
FY2025 · Dec 31, 2025
Total Current Assets
3.97BCNYFY2025 · Dec 31, 2025
Total Liabilities
4.74BCNYFY2025 · Dec 31, 2025
Total Non-current Assets
2.37BCNYFY2025 · Dec 31, 2025
Total Non-current Liabilities
747.89MCNYFY2025 · Dec 31, 2025
Total Current Liabilities
4.00BCNYFY2025 · Dec 31, 2025
Cash
247.40MCNYFY2025 · Dec 31, 2025
Cash Equivalents
339.33MCNYFY2025 · Dec 31, 2025
Cash & Cash Equivalents
586.73MCNYFY2025 · Dec 31, 2025
Other Short-term Investments
9.82MCNYFY2025 · Dec 31, 2025
Accounts Receivable
1.95BCNYFY2025 · Dec 31, 2025
Inventory
932.63MCNYFY2025 · Dec 31, 2025
Accounts Payable
812.65MCNYFY2025 · Dec 31, 2025
Short-term Debt
2.95BCNYFY2025 · Dec 31, 2025
Other Current Liabilities
3.21MCNYFY2025 · Dec 31, 2025
Long-term Debt
722.39MCNYFY2025 · Dec 31, 2025
Common Stock (Book)
205.40MCNYFY2025 · Dec 31, 2025
Retained Earnings
296.58MCNYFY2025 · Dec 31, 2025
Total Shareholders' Equity
1.59BCNY
236.58M · vs all stocks (USD)
FY2025 · Dec 31, 2025
52-Week Low
7.65CNYUpdated Aug 20, 2026
52-Week High
14.85CNYUpdated Aug 20, 2026
52-Week Change
-18.95%
vs all stocks
Updated Aug 20, 2026
Beta
0.6050x
vs all stocks
Updated Aug 20, 2026
50-Day MA
9.19CNYUpdated Aug 20, 2026
200-Day MA
11.44CNYUpdated Aug 20, 2026
Avg 10-Day Volume
4.62MSharesUpdated Aug 20, 2026
Avg 30-Day Volume
5.61MSharesUpdated Aug 20, 2026
Diluted EPS (TTM)
-1.17CNYUpdated Aug 20, 2026
1 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Money owed by customers keeps growing, and is much of its current assets.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Debt-to-equity is 2.29×, higher than 95% of its Pharmaceutical Retailers peers (median 0.7×)Significant